Navigation Links
Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors
Date:1/10/2011

SAN DIEGO, Jan. 10, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced the appointment of Dr. Hank McKinnell to its Board of Directors.  Dr. McKinnell is the former Chief Executive Officer and former Chairman of the Board of Directors of Pfizer Inc.  He is currently Chairman of the Accordia Global Health Foundation, an organization dedicated to fighting infectious diseases in Africa, and is a member of the boards of Moody's Corporation, Angiotech Pharmaceutical, Inc., and privately-held Emmaus Medical, Inc.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

"Hank McKinnell's extensive business experience, deep interest in the opportunities of the biotech industry, and dedication to profound social advances to health and wellness for patients globally makes him a valuable addition to Optimer's Board of Directors," said Pedro Lichtinger, President and CEO of Optimer. "Our ability to attract someone with Hank's business acumen and demonstrated leadership talent is an inspiration to our team. His experience in economics, strategy and business operations has been instrumental in pioneering an approach for marrying innovation, health and wellness and market access as the essential formula for success in today's pharmaceutical marketplace.  We at Optimer will benefit from his tremendous skillset and insights."

"Optimer has a unique opportunity to drive some of the most exciting innovation in health care," said Dr. McKinnell.  "Fidaxomicin is a cutting edge antibiotic for c.diff, a bacterial infection putting increasing pressure on hospitals and placing the sick and elderly at particular risk, and addresses a growing health challenge with the aging of our population – especially as the first of the Baby Boomers turn 65 this January.  With the potential FDA approval of fidaxomicin this year, it is an exciting time to be joining Optimer's Board and I look forward to working with the Optimer team."

Dr. McKinnell joined Pfizer in 1971 in Tokyo and over the years held positions of increasing responsibility around the world, including service as President of Pfizer Asia.  In 1984, Dr. McKinnell relocated to New York, where he served as Vice President-Strategic Planning, Chief Financial Officer, President-Pfizer Medical Device Group, President-Pfizer Pharmaceuticals Group, and President and Chief Operating Officer.  He was named Chairman and Chief Executive Officer in 2001 and served in this role until his retirement in 2006.

He is Chairman Emeritus of the Business Roundtable, an association of 170 CEOs of America's largest companies; the Pharmaceutical Research Manufacturers Association; the Food and Drug Law Institute; and the Medical Device Manufacturers Association. He is a member of the Academic Alliance and Chairman of the Academic Alliance Foundation, which supports infectious diseases prevention, care and treatment in Sub-Sahara Africa. Dr. McKinnell is also a Senior Advisor to TH Lee Private Equity Partnership, Toyota, and Alexander Proudfoot. He also served as Vice Chairman and a member of the Board of Trustees of the World Economic Forum, and on the President's Advisory Council on HIV/AIDS.

Recent honors include, among others, the Grand Cordon of the Order of the Rising Sun, Japan's highest award to those other than members of the Imperial Family and heads of state; the United Nations Association of the United States of America's Global Leadership Award; the Woodrow Wilson Institute Corporate Service Award; and Stanford University's Graduate School of Business Arbuckle Award and Excellence in Leadership Award.

Dr. McKinnell holds a Bachelor's Degree in business from the University of British Columbia, and M.B.A. and Ph.D. degrees from the Stanford University Graduate School of Business.

About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development, fidaxomicin and Pruvel™ (prulifloxacin).  Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI).  The Company has submitted an NDA to the FDA, and filed a MAA with the European Medicines Agency (EMA) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Forward-looking StatementsStatements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation all statements related to the anticipated development or commercialization of Optimer's product candidates and the anticipated contributions of Dr. McKinnell at Optimer. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal" and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: the timing, progress and likelihood of success of its product research and development programs, the timing and status of its applications for marketing approval its product candidates and its ability to successfully commercialize and products for which it receives marketing approval, as well as other risks detailed in Optimer's filings with the Securities and Exchange Commission. ContactsOptimer Pharmaceuticals, Inc.Christina Donaghy, Corporate Communications ManagerJohn D. Prunty, Chief Financial Officer & VP Finance858-909-0736Canale Communications, Inc.Jason I. Spark, Senior Vice President619-849-6005
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American Respiratory ... testing company, is now able to perform sophisticated lung assessments in ... Medical Technologies , Inc. Patients are no longer ... to ndd,s EasyOne PRO ® , ARL patients like Jeanne R. ... testing done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):